Literature DB >> 18471342

Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection.

Theodore C Pierson1, Michael S Diamond.   

Abstract

Flaviviruses are a group of positive-stranded RNA viruses that cause a spectrum of severe illnesses globally in more than 50 million individuals each year. While effective vaccines exist for three members of this group (yellow fever, Japanese encephalitis, and tick-borne encephalitis viruses), safe and effective vaccines for several other flaviviruses of clinical importance, including West Nile and dengue viruses, remain in development. An effective humoral immune response is critical for protection against flaviviruses and an essential goal of vaccine development. The effectiveness of virus-specific antibodies in vivo reflects their capacity to inhibit virus entry and spread through several mechanisms, including the direct neutralisation of virus infection. Recent advances in our understanding of the structural biology of flaviviruses, coupled with the use of small-animal models of flavivirus infection, have promoted significant advances in our appreciation of the factors that govern antibody recognition and inhibition of flaviviruses in vitro and in vivo. In this review, we discuss the properties that define the potency of neutralising antibodies and the molecular mechanisms by which they inhibit virus infection. How recent advances in this area have the potential to improve the development of safe and effective vaccines and immunotherapeutics is also addressed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18471342      PMCID: PMC2671962          DOI: 10.1017/S1462399408000665

Source DB:  PubMed          Journal:  Expert Rev Mol Med        ISSN: 1462-3994            Impact factor:   5.600


  142 in total

1.  Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever.

Authors:  V Churdboonchart; N Bhamarapravati; S Peampramprecha; S Sirinavin
Journal:  Am J Trop Med Hyg       Date:  1991-05       Impact factor: 2.345

2.  Antibody-dependent enhancement of dengue virus infection mediated by bispecific antibodies against cell surface molecules other than Fc gamma receptors.

Authors:  B J Mady; D V Erbe; I Kurane; M W Fanger; F A Ennis
Journal:  J Immunol       Date:  1991-11-01       Impact factor: 5.422

3.  Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions.

Authors:  F Guirakhoo; F X Heinz; C W Mandl; H Holzmann; C Kunz
Journal:  J Gen Virol       Date:  1991-06       Impact factor: 3.891

4.  Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis.

Authors:  S Pincus; P W Mason; E Konishi; B A Fonseca; R E Shope; C M Rice; E Paoletti
Journal:  Virology       Date:  1992-03       Impact factor: 3.616

5.  Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH.

Authors:  S L Allison; J Schalich; K Stiasny; C W Mandl; C Kunz; F X Heinz
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

6.  Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with protein prM.

Authors:  F X Heinz; K Stiasny; G Püschner-Auer; H Holzmann; S L Allison; C W Mandl; C Kunz
Journal:  Virology       Date:  1994-01       Impact factor: 3.616

7.  Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis.

Authors:  A D Jennings; C A Gibson; B R Miller; J H Mathews; C J Mitchell; J T Roehrig; D J Wood; F Taffs; B K Sil; S N Whitby
Journal:  J Infect Dis       Date:  1994-03       Impact factor: 5.226

8.  Antibodies to HA and NA augment uptake of influenza A viruses into cells via Fc receptor entry.

Authors:  M Tamura; R G Webster; F A Ennis
Journal:  Virology       Date:  1991-05       Impact factor: 3.616

9.  Single amino acid codon changes detected in louping ill virus antibody-resistant mutants with reduced neurovirulence.

Authors:  W R Jiang; A Lowe; S Higgs; H Reid; E A Gould
Journal:  J Gen Virol       Date:  1993-05       Impact factor: 3.891

10.  The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice.

Authors:  J J Schlesinger; M Foltzer; S Chapman
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

View more
  77 in total

1.  NIAID workshop on Flavivirus immunity.

Authors:  Alison D Augustine; M Cristina Cassetti; Francis A Ennis; Eva Harris; William H Hildebrand; Patricia M Repik
Journal:  Viral Immunol       Date:  2010-06       Impact factor: 2.257

2.  Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice.

Authors:  Juergen Zlatkovic; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

Review 3.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

4.  Impact of quaternary organization on the antigenic structure of the tick-borne encephalitis virus envelope glycoprotein E.

Authors:  Stefan Kiermayr; Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

5.  A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity.

Authors:  Atsushi Yamanaka; Tomohiro Kotaki; Eiji Konishi
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

6.  The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1.

Authors:  Yang Zhou; S Kyle Austin; Daved H Fremont; Boyd L Yount; Jeremy P Huynh; Aravinda M de Silva; Ralph S Baric; William B Messer
Journal:  Virology       Date:  2013-02-28       Impact factor: 3.616

7.  Natural strain variation and antibody neutralization of dengue serotype 3 viruses.

Authors:  Wahala M P B Wahala; Eric F Donaldson; Ruklanthi de Alwis; Mary Ann Accavitti-Loper; Ralph S Baric; Aravinda M de Silva
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

8.  Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate.

Authors:  Aaron G Schmidt; Priscilla L Yang; Stephen C Harrison
Journal:  PLoS Pathog       Date:  2010-04-08       Impact factor: 6.823

9.  Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Authors:  Scott J Balsitis; Katherine L Williams; Ruben Lachica; Diana Flores; Jennifer L Kyle; Erin Mehlhop; Syd Johnson; Michael S Diamond; P Robert Beatty; Eva Harris
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

10.  Alternative complement pathway deregulation is correlated with dengue severity.

Authors:  Eduardo J M Nascimento; Ana M Silva; Marli T Cordeiro; Carlos A Brito; Laura H V G Gil; Ulisses Braga-Neto; Ernesto T A Marques
Journal:  PLoS One       Date:  2009-08-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.